-
1
-
-
0037187568
-
Conceptual biology: unearthing the gems
-
Blagosklonny MV, Pardee AB. Conceptual biology: unearthing the gems. Nature. 2002; 416: 373.
-
(2002)
Nature
, vol.416
, pp. 373
-
-
Blagosklonny, M.V.1
Pardee, A.B.2
-
2
-
-
34547658080
-
Research by retrieving experiments
-
Blagosklonny MV. Research by retrieving experiments. Cell Cycle. 2007; 6: 1277-1283.
-
(2007)
Cell Cycle
, vol.6
, pp. 1277-1283
-
-
Blagosklonny, M.V.1
-
3
-
-
0031417677
-
Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy
-
Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, Arber N, Ciaparrone M, Yamamoto H. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res. 1997; 3: 2696-2702.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 2696-2702
-
-
Weinstein, I.B.1
Begemann, M.2
Zhou, P.3
Han, E.K.4
Sgambato, A.5
Doki, Y.6
Arber, N.7
Ciaparrone, M.8
Yamamoto, H.9
-
4
-
-
0037025173
-
Addiction to oncogenes--the Achilles heal of cancer
-
Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297: 63-64.
-
(2002)
Science
, vol.297
, pp. 63-64
-
-
Weinstein, I.B.1
-
5
-
-
44849093562
-
Oncogene addiction
-
discussion 2008
-
Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008; 68: 3077-3080; discussion 3080.
-
Cancer Res
, vol.68
, pp. 3077-3080
-
-
Weinstein, I.B.1
Joe, A.2
-
6
-
-
4644274700
-
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
-
Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med. 2004; 10: 481-486.
-
(2004)
Trends Mol Med
, vol.10
, pp. 481-486
-
-
Gazdar, A.F.1
Shigematsu, H.2
Herz, J.3
Minna, J.D.4
-
7
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
Kris, M.14
Varmus, H.15
-
8
-
-
0035893318
-
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
-
Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001; 15: 3249-3262.
-
(2001)
Genes Dev
, vol.15
, pp. 3249-3262
-
-
Fisher, G.H.1
Wellen, S.L.2
Klimstra, D.3
Lenczowski, J.M.4
Tichelaar, J.W.5
Lizak, M.J.6
Whitsett, J.A.7
Koretsky, A.8
Varmus, H.E.9
-
9
-
-
33750627972
-
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes
-
Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006; 10: 425- 435.
-
(2006)
Cancer Cell
, vol.10
, pp. 425-435
-
-
Sharma, S.V.1
Gajowniczek, P.2
Way, I.P.3
Lee, D.Y.4
Jiang, J.5
Yuza, Y.6
Classon, M.7
Haber, D.A.8
Settleman, J.9
-
10
-
-
33744814638
-
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
-
Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006; 20: 1496-1510.
-
(2006)
Genes Dev
, vol.20
, pp. 1496-1510
-
-
Politi, K.1
Zakowski, M.F.2
Fan, P.D.3
Schonfeld, E.A.4
Pao, W.5
Varmus, H.E.6
-
11
-
-
33845645365
-
Oncogenic shock: turning an activated kinase against the tumor cell
-
Sharma SV, Settleman J. Oncogenic shock: turning an activated kinase against the tumor cell. Cell Cycle. 2006; 5: 2878-2880.
-
(2006)
Cell Cycle
, vol.5
, pp. 2878-2880
-
-
Sharma, S.V.1
Settleman, J.2
-
12
-
-
32044445067
-
TORgeting oncogene addiction for cancer therapy
-
Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell. 2006; 9: 77-79.
-
(2006)
Cancer Cell
, vol.9
, pp. 77-79
-
-
Choo, A.Y.1
Blenis, J.2
-
14
-
-
34548785473
-
Non-oncogene addiction and the stress phenotype of cancer cells
-
Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130: 986-988.
-
(2007)
Cell
, vol.130
, pp. 986-988
-
-
Solimini, N.L.1
Luo, J.2
Elledge, S.J.3
-
15
-
-
37249003928
-
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
-
Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007; 21: 3214-3231.
-
(2007)
Genes Dev
, vol.21
, pp. 3214-3231
-
-
Sharma, S.V.1
Settleman, J.2
-
16
-
-
34548771087
-
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
-
Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007; 104: 13028-13033.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 13028-13033
-
-
Wu, C.H.1
van Riggelen, J.2
Yetil, A.3
Fan, A.C.4
Bachireddy, P.5
Felsher, D.W.6
-
17
-
-
44849137232
-
Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
-
discussion 3086
-
Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 2008; 68: 3081-3086; discussion 3086.
-
(2008)
Cancer Res
, vol.68
, pp. 3081-3086
-
-
Felsher, D.W.1
-
18
-
-
42449105650
-
Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras
-
Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A. 2008; 105: 5242- 5247.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 5242-5247
-
-
Podsypanina, K.1
Politi, K.2
Beverly, L.J.3
Varmus, H.E.4
-
19
-
-
55949101858
-
Kinase requirements in human cells: III Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
-
Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG, Jr., Grueneberg DA. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A. 2008; 105: 16484-16489.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 16484-16489
-
-
Bommi-Reddy, A.1
Almeciga, I.2
Sawyer, J.3
Geisen, C.4
Li, W.5
Harlow, E.6
Kaelin Jr., W.G.7
Grueneberg, D.A.8
-
20
-
-
70350247869
-
MYC, microRNAs and glutamine addiction in cancers
-
Dang CV. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle. 2009; 8: 3243-3245.
-
(2009)
Cell Cycle
, vol.8
, pp. 3243-3245
-
-
Dang, C.V.1
-
21
-
-
69749120104
-
Oncogenic K-ras "addiction" and synthetic lethality
-
Singh A, Settleman J. Oncogenic K-ras "addiction" and synthetic lethality. Cell Cycle. 2009; 8: 2676-2677.
-
(2009)
Cell Cycle
, vol.8
, pp. 2676-2677
-
-
Singh, A.1
Settleman, J.2
-
22
-
-
77953500567
-
Differences underlying EGFR and HER2 oncogene addiction
-
Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle. 2010; 9: 851-852.
-
(2010)
Cell Cycle
, vol.9
, pp. 851-852
-
-
Faber, A.C.1
Wong, K.K.2
Engelman, J.A.3
-
23
-
-
77953507642
-
Targeting the degradation of cyclin D1 will help to eliminate oncogene addiction
-
Lee JT, Shan J, Gu W. Targeting the degradation of cyclin D1 will help to eliminate oncogene addiction. Cell Cycle. 2010; 9: 857-858.
-
(2010)
Cell Cycle
, vol.9
, pp. 857-858
-
-
Lee, J.T.1
Shan, J.2
Gu, W.3
-
24
-
-
79952666779
-
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction
-
Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P, Poli V. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010; 2: 823-842.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 823-842
-
-
Demaria, M.1
Giorgi, C.2
Lebiedzinska, M.3
Esposito, G.4
D'Angeli, L.5
Bartoli, A.6
Gough, D.J.7
Turkson, J.8
Levy, D.E.9
Watson, C.J.10
Wieckowski, M.R.11
Provero, P.12
Pinton, P.13
Poli, V.14
-
25
-
-
79952255381
-
STAT3, HIF-1, glucose addiction and Warburg effect
-
Darnell JE, Jr. STAT3, HIF-1, glucose addiction and Warburg effect. Aging (Albany NY). 2010; 2: 890-891.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 890-891
-
-
Darnell Jr, J.E.1
-
26
-
-
79957523953
-
Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?
-
Jeang KT. Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget. 2010; 1: 453-456.
-
(2010)
Oncotarget
, vol.1
, pp. 453-456
-
-
Jeang, K.T.1
-
27
-
-
80051701028
-
Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop
-
Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G, Sala A. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget. 2010; 1: 278-288.
-
(2010)
Oncotarget
, vol.1
, pp. 278-288
-
-
Gualdrini, F.1
Corvetta, D.2
Cantilena, S.3
Chayka, O.4
Tanno, B.5
Raschella, G.6
Sala, A.7
-
28
-
-
70350435633
-
Shifting paradigms: the seeds of oncogene addiction
-
Sawyers CL. Shifting paradigms: the seeds of oncogene addiction. Nat Med. 2009; 15: 1158-1161.
-
(2009)
Nat Med
, vol.15
, pp. 1158-1161
-
-
Sawyers, C.L.1
-
29
-
-
61449182121
-
Principles of cancer therapy: oncogene and non-oncogene addiction
-
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136: 823-837.
-
(2009)
Cell
, vol.136
, pp. 823-837
-
-
Luo, J.1
Solimini, N.L.2
Elledge, S.J.3
-
30
-
-
80054830482
-
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction
-
Choi PS, van Riggelen J, Gentles AJ, Bachireddy P, Rakhra K, Adam SJ, Plevritis SK, Felsher DW. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci U S A. 2011; 108: 17432- 17437.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 17432-17437
-
-
Choi, P.S.1
van Riggelen, J.2
Gentles, A.J.3
Bachireddy, P.4
Rakhra, K.5
Adam, S.J.6
Plevritis, S.K.7
Felsher, D.W.8
-
31
-
-
10944269712
-
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers
-
Blagosklonny MV. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers. Cancer Biol Ther. 2004; 3: 436-440.
-
(2004)
Cancer Biol Ther
, vol.3
, pp. 436-440
-
-
Blagosklonny, M.V.1
-
32
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112: 4808-4817.
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, B.J.1
-
33
-
-
56849117387
-
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis
-
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008; 14: 485-493.
-
(2008)
Cancer Cell
, vol.14
, pp. 485-493
-
-
Shah, N.P.1
Kasap, C.2
Weier, C.3
Balbas, M.4
Nicoll, J.M.5
Bleickardt, E.6
Nicaise, C.7
Sawyers, C.L.8
-
34
-
-
0032032270
-
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
-
Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998; 91: 1700-1705.
-
(1998)
Blood
, vol.91
, pp. 1700-1705
-
-
Amarante-Mendes, G.P.1
Naekyung Kim, C.2
Liu, L.3
Huang, Y.4
Perkins, C.L.5
Green, D.R.6
Bhalla, K.7
-
35
-
-
0034142368
-
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP Bcl- 2 or Bcl-x(L)
-
Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl- 2, or Bcl-x(L). Blood. 2000; 95: 1014-1022.
-
(2000)
Blood
, vol.95
, pp. 1014-1022
-
-
Perkins, C.1
Kim, C.N.2
Fang, G.3
Bhalla, K.N.4
-
36
-
-
0034794098
-
Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death?
-
Blagosklonny MV. Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays. 2001; 23: 947-953.
-
(2001)
Bioessays
, vol.23
, pp. 947-953
-
-
Blagosklonny, M.V.1
-
37
-
-
0036044841
-
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor
-
Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA, Gudkov AV. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther. 2002; 1: 39-44.
-
(2002)
Cancer Biol Ther
, vol.1
, pp. 39-44
-
-
Gurova, K.V.1
Kwek, S.S.2
Koman, I.E.3
Komarov, A.P.4
Kandel, E.5
Nikiforov, M.A.6
Gudkov, A.V.7
-
38
-
-
0037216725
-
Paradoxical role of apoptosis in tumor progression
-
Gurova KV, Gudkov AV. Paradoxical role of apoptosis in tumor progression. J Cell Biochem. 2003; 88: 128-137.
-
(2003)
J Cell Biochem
, vol.88
, pp. 128-137
-
-
Gurova, K.V.1
Gudkov, A.V.2
-
39
-
-
1542299692
-
Do cells need CDK2 and Bcr-Abl?
-
Blagosklonny MV. Do cells need CDK2 and... Bcr-Abl? Cell Death Differ. 2004; 11: 249-251.
-
(2004)
Cell Death Differ
, vol.11
, pp. 249-251
-
-
Blagosklonny, M.V.1
-
40
-
-
25144483367
-
Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1- expressing cells to imatinib and geldanamycin
-
Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1- expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 2005; 4: 484-490.
-
(2005)
Cancer Biol Ther
, vol.4
, pp. 484-490
-
-
Demidenko, Z.N.1
An, W.G.2
Lee, J.T.3
Romanova, L.Y.4
McCubrey, J.A.5
Blagosklonny, M.V.6
-
41
-
-
25444497278
-
The concept of synthetic lethality in the context of anticancer therapy
-
Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005; 5: 689-698.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 689-698
-
-
Kaelin Jr., W.G.1
-
42
-
-
78649645676
-
Synthetic lethal approaches to breast cancer therapy
-
Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol. 2010; 7: 718-724.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 718-724
-
-
Rehman, F.L.1
Lord, C.J.2
Ashworth, A.3
-
43
-
-
77953575202
-
Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality
-
Bauzon F, Zhu L. Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle. 2010; 9: 2118-2123.
-
(2010)
Cell Cycle
, vol.9
, pp. 2118-2123
-
-
Bauzon, F.1
Zhu, L.2
-
44
-
-
70349912096
-
Exploiting synthetic lethal interactions for targeted cancer therapy
-
Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009; 8: 3112-3119.
-
(2009)
Cell Cycle
, vol.8
, pp. 3112-3119
-
-
Reinhardt, H.C.1
Jiang, H.2
Hemann, M.T.3
Yaffe, M.B.4
-
45
-
-
79957722003
-
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
-
Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011; 108: 8773-8778.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 8773-8778
-
-
Shaw, A.T.1
Winslow, M.M.2
Magendantz, M.3
Ouyang, C.4
Dowdle, J.5
Subramanian, A.6
Lewis, T.A.7
Maglathin, R.L.8
Tolliday, N.9
Jacks, T.10
-
46
-
-
74849113809
-
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications
-
Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle. 2009; 8: 3960-3970.
-
(2009)
Cell Cycle
, vol.8
, pp. 3960-3970
-
-
Neznanov, N.1
Gorbachev, A.V.2
Neznanova, L.3
Komarov, A.P.4
Gurova, K.V.5
Gasparian, A.V.6
Banerjee, A.K.7
Almasan, A.8
Fairchild, R.L.9
Gudkov, A.V.10
-
47
-
-
80052066877
-
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib
-
Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011; 2: 209-221.
-
(2011)
Oncotarget
, vol.2
, pp. 209-221
-
-
Neznanov, N.1
Komarov, A.P.2
Neznanova, L.3
Stanhope-Baker, P.4
Gudkov, A.V.5
-
48
-
-
0036513029
-
Oncogenic resistance to growth-limiting conditions
-
Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer. 2002; 2: 221-225.
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 221-225
-
-
Blagosklonny, M.V.1
-
49
-
-
29244479554
-
Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance
-
Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005; 4: 1693-1698.
-
(2005)
Cell Cycle
, vol.4
, pp. 1693-1698
-
-
Blagosklonny, M.V.1
-
50
-
-
42449144748
-
Antagonistic drug combinations that select against drug resistance: from bacteria to cancer
-
Blagosklonny MV. Antagonistic drug combinations that select against drug resistance: from bacteria to cancer. Cancer Biol Ther. 2007; 6: 1013-1014.
-
(2007)
Cancer Biol Ther
, vol.6
, pp. 1013-1014
-
-
Blagosklonny, M.V.1
-
51
-
-
0032715399
-
Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal
-
Blagosklonny MV. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia. 1999; 13: 2031-2035.
-
(1999)
Leukemia
, vol.13
, pp. 2031-2035
-
-
Blagosklonny, M.V.1
-
52
-
-
0034235610
-
Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells
-
Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res. 2000; 60: 3425- 3428.
-
(2000)
Cancer Res
, vol.60
, pp. 3425-3428
-
-
Blagosklonny, M.V.1
Bishop, P.C.2
Robey, R.3
Fojo, T.4
Bates, S.E.5
-
53
-
-
0033997563
-
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
-
Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest. 2000; 105: 533-539.
-
(2000)
J Clin Invest
, vol.105
, pp. 533-539
-
-
Blagosklonny, M.V.1
Robey, R.2
Bates, S.3
Fojo, T.4
-
54
-
-
0034988902
-
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells
-
Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia. 2001; 15: 936- 941.
-
(2001)
Leukemia
, vol.15
, pp. 936-941
-
-
Blagosklonny, M.V.1
-
55
-
-
0037068773
-
Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs
-
Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002; 21: 6249- 6254.
-
(2002)
Oncogene
, vol.21
, pp. 6249-6254
-
-
Blagosklonny, M.V.1
-
56
-
-
20144377122
-
Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1- expressing) cancer cells by docetaxel
-
Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1- expressing) cancer cells by docetaxel. Cancer Res. 2005; 65: 4401-4407.
-
(2005)
Cancer Res
, vol.65
, pp. 4401-4407
-
-
Demidenko, Z.N.1
Halicka, D.2
Kunicki, J.3
McCubrey, J.A.4
Darzynkiewicz, Z.5
Blagosklonny, M.V.6
-
57
-
-
16444380911
-
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors
-
Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005; 65: 1918-1924.
-
(2005)
Cancer Res
, vol.65
, pp. 1918-1924
-
-
Carvajal, D.1
Tovar, C.2
Yang, H.3
Vu, B.T.4
Heimbrook, D.C.5
Vassilev, L.T.6
-
58
-
-
62649112876
-
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
-
Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009; 106: 3964-3969.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 3964-3969
-
-
Sur, S.1
Pagliarini, R.2
Bunz, F.3
Rago, C.4
Diaz Jr., L.A.5
Kinzler, K.W.6
Vogelstein, B.7
Papadopoulos, N.8
-
59
-
-
69749128490
-
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy
-
Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle. 2009; 8: 2810-2818.
-
(2009)
Cell Cycle
, vol.8
, pp. 2810-2818
-
-
Choong, M.L.1
Yang, H.2
Lee, M.A.3
Lane, D.P.4
-
60
-
-
77955709042
-
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
-
Cheok CF, Kua N, Kaldis P, Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ. 2010; 17: 1486-1500.
-
(2010)
Cell Death Differ
, vol.17
, pp. 1486-1500
-
-
Cheok, C.F.1
Kua, N.2
Kaldis, P.3
Lane, D.P.4
-
61
-
-
79956035239
-
Evaluation of an Actinomycin D/ VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
-
Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/ VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1: 639-650.
-
(2010)
Oncotarget
, vol.1
, pp. 639-650
-
-
Rao, B.1
van Leeuwen, I.M.2
Higgins, M.3
Campbel, J.4
Thompson, A.M.5
Lane, D.P.6
Lain, S.7
-
62
-
-
79960464440
-
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture
-
Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011; 2: 222-233.
-
(2011)
Oncotarget
, vol.2
, pp. 222-233
-
-
Apontes, P.1
Leontieva, O.V.2
Demidenko, Z.N.3
Li, F.4
Blagosklonny, M.V.5
-
63
-
-
0033543728
-
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
-
Komarov PG, Komarova EA, Kondratov RV, Christov- Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285: 1733-1737.
-
(1999)
Science
, vol.285
, pp. 1733-1737
-
-
Komarov, P.G.1
Komarova, E.A.2
Kondratov, R.V.3
Christov-Tselkov, K.4
Coon, J.S.5
Chernov, M.V.6
Gudkov, A.V.7
-
64
-
-
0035884487
-
Chemoprotection from p53- dependent apoptosis: potential clinical applications of the p53 inhibitors
-
Komarova EA, Gudkov AV. Chemoprotection from p53- dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol. 2001; 62: 657-667.
-
(2001)
Biochem Pharmacol
, vol.62
, pp. 657-667
-
-
Komarova, E.A.1
Gudkov, A.V.2
-
65
-
-
0042928366
-
Targeting cancer cells by exploiting their resistance
-
Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med. 2003; 9: 307-312.
-
(2003)
Trends Mol Med
, vol.9
, pp. 307-312
-
-
Blagosklonny, M.V.1
-
66
-
-
33747620737
-
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation
-
Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, Komarova EA, Gudkov AV. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol. 2006; 2: 474-479.
-
(2006)
Nat Chem Biol
, vol.2
, pp. 474-479
-
-
Strom, E.1
Sathe, S.2
Komarov, P.G.3
Chernova, O.B.4
Pavlovska, I.5
Shyshynova, I.6
Bosykh, D.A.7
Burdelya, L.G.8
Macklis, R.M.9
Skaliter, R.10
Komarova, E.A.11
Gudkov, A.V.12
-
67
-
-
42049095095
-
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models
-
Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008; 320: 226-230.
-
(2008)
Science
, vol.320
, pp. 226-230
-
-
Burdelya, L.G.1
Krivokrysenko, V.I.2
Tallant, T.C.3
Strom, E.4
Gleiberman, A.S.5
Gupta, D.6
Kurnasov, O.V.7
Fort, F.L.8
Osterman, A.L.9
Didonato, J.A.10
Feinstein, E.11
Gudkov, A.V.12
-
68
-
-
84858971464
-
Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy
-
Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV. Toll-like Receptor 5 Agonist Protects Mice from Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy. Int J Radiat Oncol Biol Phys. 2011.
-
(2011)
Int J Radiat Oncol Biol Phys
-
-
Burdelya, L.G.1
Gleiberman, A.S.2
Toshkov, I.3
Aygun-Sunar, S.4
Bapardekar, M.5
Manderscheid-Kern, P.6
Bellnier, D.7
Krivokrysenko, V.I.8
Feinstein, E.9
Gudkov, A.V.10
-
69
-
-
0035359505
-
Exploiting cancer cell cycling for selective protection of normal cells
-
Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001; 61: 4301-4305.
-
(2001)
Cancer Res
, vol.61
, pp. 4301-4305
-
-
Blagosklonny, M.V.1
Pardee, A.B.2
-
70
-
-
0012177733
-
Cyclotherapy: protection of normal cells and unshielding of cancer cells
-
Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle. 2002; 1: 375-382.
-
(2002)
Cell Cycle
, vol.1
, pp. 375-382
-
-
Blagosklonny, M.V.1
Darzynkiewicz, Z.2
-
71
-
-
45749117120
-
"Targeting the absence" and therapeutic engineering for cancer therapy
-
Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle. 2008; 7: 1307-1312
-
(2008)
Cell Cycle
, vol.7
, pp. 1307-1312
-
-
Blagosklonny, M.V.1
-
72
-
-
77955001669
-
Radioprotection: smart games with death
-
Gudkov AV, Komarova EA. Radioprotection: smart games with death. J Clin Invest. 2010; 120: 2270-2273.
-
(2010)
J Clin Invest
, vol.120
, pp. 2270-2273
-
-
Gudkov, A.V.1
Komarova, E.A.2
-
73
-
-
77953642929
-
Fasting and cancer treatment in humans: A case series report
-
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009; 1: 988-1007.
-
(2009)
Aging (Albany NY)
, vol.1
, pp. 988-1007
-
-
Safdie, F.M.1
Dorff, T.2
Quinn, D.3
Fontana, L.4
Wei, M.5
Lee, C.6
Cohen, P.7
Longo, V.D.8
-
74
-
-
23644433384
-
How cancer could be cured by 2015
-
Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle. 2005; 4: 269-278.
-
(2005)
Cell Cycle
, vol.4
, pp. 269-278
-
-
Blagosklonny, M.V.1
-
78
-
-
4043181214
-
Cancer genes and the pathways they control
-
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-799.
-
(2004)
Nat Med
, vol.10
, pp. 789-799
-
-
Vogelstein, B.1
Kinzler, K.W.2
-
79
-
-
78249261016
-
Accumulation of driver and passenger mutations during tumor progression
-
Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A. 2010; 107: 18545-18550.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 18545-18550
-
-
Bozic, I.1
Antal, T.2
Ohtsuki, H.3
Carter, H.4
Kim, D.5
Chen, S.6
Karchin, R.7
Kinzler, K.W.8
Vogelstein, B.9
Nowak, M.A.10
-
80
-
-
80054686286
-
Tumor metastasis: molecular insights and evolving paradigms
-
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147: 275-292.
-
(2011)
Cell
, vol.147
, pp. 275-292
-
-
Valastyan, S.1
Weinberg, R.A.2
-
81
-
-
36949025507
-
Genetic progression and the waiting time to cancer
-
Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. Genetic progression and the waiting time to cancer. PLoS Comput Biol. 2007; 3: e225.
-
(2007)
PLoS Comput Biol
, vol.3
-
-
Beerenwinkel, N.1
Antal, T.2
Dingli, D.3
Traulsen, A.4
Kinzler, K.W.5
Velculescu, V.E.6
Vogelstein, B.7
Nowak, M.A.8
-
82
-
-
78049380554
-
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
-
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467: 1109-1113.
-
(2010)
Nature
, vol.467
, pp. 1109-1113
-
-
Campbell, P.J.1
Yachida, S.2
Mudie, L.J.3
Stephens, P.J.4
Pleasance, E.D.5
Stebbings, L.A.6
Morsberger, L.A.7
Latimer, C.8
McLaren, S.9
Lin, M.L.10
McBride, D.J.11
Varela, I.12
Nik-Zainal, S.A.13
Leroy, C.14
Jia, M.15
Menzies, A.16
-
83
-
-
69249115697
-
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations
-
Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009; 69: 6660-6667.
-
(2009)
Cancer Res
, vol.69
, pp. 6660-6667
-
-
Carter, H.1
Chen, S.2
Isik, L.3
Tyekucheva, S.4
Velculescu, V.E.5
Kinzler, K.W.6
Vogelstein, B.7
Karchin, R.8
-
84
-
-
36248962105
-
The genomic landscapes of human breast and colorectal cancers
-
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-1113.
-
(2007)
Science
, vol.318
, pp. 1108-1113
-
-
Wood, L.D.1
Parsons, D.W.2
Jones, S.3
Lin, J.4
Sjoblom, T.5
Leary, R.J.6
Shen, D.7
Boca, S.M.8
Barber, T.9
Ptak, J.10
Silliman, N.11
Szabo, S.12
Dezso, Z.13
Ustyanksky, V.14
Nikolskaya, T.15
Nikolsky, Y.16
-
85
-
-
68049097111
-
Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair
-
Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, Powell SN, Bhat A, Yaguchi T, Wadhwa R et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009; 8: 2198-2210.
-
(2009)
Cell Cycle
, vol.8
, pp. 2198-2210
-
-
Gupta, A.1
Yang, Q.2
Pandita, R.K.3
Hunt, C.R.4
Xiang, T.5
Misri, S.6
Zeng, S.7
Pagan, J.8
Jeffery, J.9
Puc, J.10
Kumar, R.11
Feng, Z.12
Powell, S.N.13
Bhat, A.14
Yaguchi, T.15
Wadhwa, R.16
-
86
-
-
0037184909
-
Taking the study of cancer cell survival to a new dimension
-
Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell. 2002; 111: 923-925.
-
(2002)
Cell
, vol.111
, pp. 923-925
-
-
Jacks, T.1
Weinberg, R.A.2
-
87
-
-
23844445836
-
Colorectal cancer: mutations in a signalling pathway
-
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature. 2005; 436: 792.
-
(2005)
Nature
, vol.436
, pp. 792
-
-
Parsons, D.W.1
Wang, T.L.2
Samuels, Y.3
Bardelli, A.4
Cummins, J.M.5
DeLong, L.6
Silliman, N.7
Ptak, J.8
Szabo, S.9
Willson, J.K.10
Markowitz, S.11
Kinzler, K.W.12
Vogelstein, B.13
Lengauer, C.14
Velculescu, V.E.15
-
88
-
-
0028931152
-
Inhibition of ras-induced proliferation and cellular transformation by p16INK4
-
Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar- Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science. 1995; 267: 249-252.
-
(1995)
Science
, vol.267
, pp. 249-252
-
-
Serrano, M.1
Gomez-Lahoz, E.2
DePinho, R.A.3
Beach, D.4
Bar-Sagi, D.5
-
89
-
-
35948967957
-
p53 determines multidrug sensitivity of childhood neuroblastoma
-
Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, Gurova KV, Norris MD, Gudkov AV. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 2007; 67: 10351-10360.
-
(2007)
Cancer Res
, vol.67
, pp. 10351-10360
-
-
Xue, C.1
Haber, M.2
Flemming, C.3
Marshall, G.M.4
Lock, R.B.5
MacKenzie, K.L.6
Gurova, K.V.7
Norris, M.D.8
Gudkov, A.V.9
-
90
-
-
33846899456
-
Restoration of p53 function leads to tumour regression in vivo
-
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445: 661-665.
-
(2007)
Nature
, vol.445
, pp. 661-665
-
-
Ventura, A.1
Kirsch, D.G.2
McLaughlin, M.E.3
Tuveson, D.A.4
Grimm, J.5
Lintault, L.6
Newman, J.7
Reczek, E.E.8
Weissleder, R.9
Jacks, T.10
-
91
-
-
79957891587
-
Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis
-
Young NP, Crowley D, Jacks T. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 2011; 71: 4040-4047.
-
(2011)
Cancer Res
, vol.71
, pp. 4040-4047
-
-
Young, N.P.1
Crowley, D.2
Jacks, T.3
-
92
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
93
-
-
1642472018
-
Antiangiogenic therapy and tumor progression
-
Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5: 13-17.
-
(2004)
Cancer Cell
, vol.5
, pp. 13-17
-
-
Blagosklonny, M.V.1
-
94
-
-
77950923924
-
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer
-
Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010; 24: 837-852.
-
(2010)
Genes Dev
, vol.24
, pp. 837-852
-
-
Oliver, T.G.1
Mercer, K.L.2
Sayles, L.C.3
Burke, J.R.4
Mendus, D.5
Lovejoy, K.S.6
Cheng, M.H.7
Subramanian, A.8
Mu, D.9
Powers, S.10
Crowley, D.11
Bronson, R.T.12
Whittaker, C.A.13
Bhutkar, A.14
Lippard, S.J.15
Golub, T.16
-
95
-
-
78049398107
-
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
-
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio- Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467: 1114-1117.
-
(2010)
Nature
, vol.467
, pp. 1114-1117
-
-
Yachida, S.1
Jones, S.2
Bozic, I.3
Antal, T.4
Leary, R.5
Fu, B.6
Kamiyama, M.7
Hruban, R.H.8
Eshleman, J.R.9
Nowak, M.A.10
Velculescu, V.E.11
Kinzler, K.W.12
Vogelstein, B.13
Iacobuzio-Donahue, C.A.14
-
96
-
-
33751252276
-
Cancer metastasis: building a framework
-
Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-695.
-
(2006)
Cell
, vol.127
, pp. 679-695
-
-
Gupta, G.P.1
Massague, J.2
-
97
-
-
0028025563
-
Apoptosis in cancer therapy: crossing the threshold
-
Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994; 78: 539-542.
-
(1994)
Cell
, vol.78
, pp. 539-542
-
-
Fisher, D.E.1
-
98
-
-
0027987067
-
Apoptosis as a goal of cancer therapy
-
Martin SJ, Green DR. Apoptosis as a goal of cancer therapy. Curr Opin Oncol. 1994; 6: 616-621.
-
(1994)
Curr Opin Oncol
, vol.6
, pp. 616-621
-
-
Martin, S.J.1
Green, D.R.2
-
99
-
-
0032748746
-
Apoptosis and drug response
-
Houghton JA. Apoptosis and drug response. Curr Opin Oncol. 1999; 11: 475-481.
-
(1999)
Curr Opin Oncol
, vol.11
, pp. 475-481
-
-
Houghton, J.A.1
-
100
-
-
0032877668
-
Dysregulation of apoptosis in cancer
-
Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999; 17: 2941-2953.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2941-2953
-
-
Reed, J.C.1
-
101
-
-
0033026714
-
Mechanisms of apoptosis avoidance in cancer
-
Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999; 11: 68-75.
-
(1999)
Curr Opin Oncol
, vol.11
, pp. 68-75
-
-
Reed, J.C.1
-
102
-
-
0033400809
-
Apoptosis and cancer drug targeting
-
Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest. 1999; 104: 1655-1661.
-
(1999)
J Clin Invest
, vol.104
, pp. 1655-1661
-
-
Sellers, W.R.1
Fisher, D.E.2
-
103
-
-
0033564103
-
Dead or dying: Necrosis versus apoptosis in caspase-deficient human renal cell carcinoma
-
Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, Finke JH. Dead or dying: Necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res. 1999; 59: 2838-2842.
-
(1999)
Cancer Res
, vol.59
, pp. 2838-2842
-
-
Kolenko, V.1
Uzzo, R.G.2
Bukowski, R.3
Bander, N.H.4
Novick, A.C.5
Hsi, E.D.6
Finke, J.H.7
-
105
-
-
0037169358
-
Apoptosis: a link between cancer genetics and chemotherapy
-
Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108: 153-164.
-
(2002)
Cell
, vol.108
, pp. 153-164
-
-
Johnstone, R.W.1
Ruefli, A.A.2
Lowe, S.W.3
-
106
-
-
1542472979
-
Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?
-
Brown JM, Wilson G. Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther. 2003; 2: 477-490.
-
(2003)
Cancer Biol Ther
, vol.2
, pp. 477-490
-
-
Brown, J.M.1
Wilson, G.2
-
107
-
-
0035736138
-
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells
-
Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001; 4: 303- 313.
-
(2001)
Drug Resist Updat
, vol.4
, pp. 303-313
-
-
Roninson, I.B.1
Broude, E.V.2
Chang, B.D.3
-
108
-
-
0036815596
-
Tumor senescence as a determinant of drug response in vivo
-
Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat. 2002; 5: 204-208.
-
(2002)
Drug Resist Updat
, vol.5
, pp. 204-208
-
-
Roninson, I.B.1
-
109
-
-
3543092021
-
Pathways of apoptotic and non-apoptotic death in tumour cells
-
Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004; 4: 592-603.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 592-603
-
-
Okada, H.1
Mak, T.W.2
-
110
-
-
0033867955
-
Cell death beyond apoptosis
-
Blagosklonny MV. Cell death beyond apoptosis. Leukemia. 2000; 14: 1502-1508.
-
(2000)
Leukemia
, vol.14
, pp. 1502-1508
-
-
Blagosklonny, M.V.1
-
111
-
-
0036491526
-
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death
-
Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther. 2002; 1: 113- 117.
-
(2002)
Cancer Biol Ther
, vol.1
, pp. 113-117
-
-
Blagosklonny, M.V.1
Robey, R.2
Sheikh, M.S.3
Fojo, T.4
-
112
-
-
0029929672
-
Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
-
Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 1996; 56: 1834-1841.
-
(1996)
Cancer Res
, vol.56
, pp. 1834-1841
-
-
Chresta, C.M.1
Masters, J.R.2
Hickman, J.A.3
-
113
-
-
77953571903
-
p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors
-
Li B, Cheng Q, Li Z, Chen J. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle. 2010; 9: 1411-1420.
-
(2010)
Cell Cycle
, vol.9
, pp. 1411-1420
-
-
Li, B.1
Cheng, Q.2
Li, Z.3
Chen, J.4
-
114
-
-
0032493125
-
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
-
Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene. 1998; 16: 2345-2349.
-
(1998)
Oncogene
, vol.16
, pp. 2345-2349
-
-
Houldsworth, J.1
Xiao, H.2
Murty, V.V.3
Chen, W.4
Ray, B.5
Reuter, V.E.6
Bosl, G.J.7
Chaganti, R.S.8
-
115
-
-
79955447216
-
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin
-
Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE, van der Kuip H. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One. 2011; 6: e19198.
-
(2011)
PLoS One
, vol.6
-
-
Gutekunst, M.1
Oren, M.2
Weilbacher, A.3
Dengler, M.A.4
Markwardt, C.5
Thomale, J.6
Aulitzky, W.E.7
van der Kuip, H.8
-
116
-
-
34247596509
-
Late relapse of testis cancer
-
abstract x-xi
-
Ehrlich Y, Baniel J. Late relapse of testis cancer. Urol Clin North Am. 2007; 34: 253-258; abstract x-xi.
-
(2007)
Urol Clin North Am
, vol.34
, pp. 253-258
-
-
Ehrlich, Y.1
Baniel, J.2
-
117
-
-
81255147796
-
Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis
-
Vestergaard AL, Thorup K, Knudsen UB, Munk T, Rosbach H, Poulsen JB, Guldberg P, Martensen PM. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod. 2011; 17: 758-761.
-
(2011)
Mol Hum Reprod
, vol.17
, pp. 758-761
-
-
Vestergaard, A.L.1
Thorup, K.2
Knudsen, U.B.3
Munk, T.4
Rosbach, H.5
Poulsen, J.B.6
Guldberg, P.7
Martensen, P.M.8
-
118
-
-
79251629946
-
The genetic landscape of the childhood cancer medulloblastoma
-
Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331: 435-439.
-
(2011)
Science
, vol.331
, pp. 435-439
-
-
Parsons, D.W.1
Li, M.2
Zhang, X.3
Jones, S.4
Leary, R.J.5
Lin, J.C.6
Boca, S.M.7
Carter, H.8
Samayoa, J.9
Bettegowda, C.10
Gallia, G.L.11
Jallo, G.I.12
Binder, Z.A.13
Nikolsky, Y.14
Hartigan, J.15
Smith, D.R.16
-
119
-
-
79954626829
-
Hypoglycemic/ hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs
-
Onozuka H, Tsuchihara K, Esumi H. Hypoglycemic/ hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci. 2011; 102: 975-982.
-
(2011)
Cancer Sci
, vol.102
, pp. 975-982
-
-
Onozuka, H.1
Tsuchihara, K.2
Esumi, H.3
-
120
-
-
83755186554
-
Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression
-
Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging (Albany NY). 2011; 3: 1078-1091.
-
(2011)
Aging (Albany NY)
, vol.3
, pp. 1078-1091
-
-
Leontieva, O.V.1
Blagosklonny, M.V.2
-
121
-
-
0038441503
-
Cell senescence and hypermitogenic arrest
-
Blagosklonny MV. Cell senescence and hypermitogenic arrest. EMBO Rep. 2003; 4: 358-362.
-
(2003)
EMBO Rep
, vol.4
, pp. 358-362
-
-
Blagosklonny, M.V.1
-
122
-
-
79957880743
-
Cell cycle arrest is not senescence
-
Blagosklonny MV. Cell cycle arrest is not senescence. Aging (Albany NY). 2011; 3: 94-101.
-
(2011)
Aging (Albany NY)
, vol.3
, pp. 94-101
-
-
Blagosklonny, M.V.1
-
123
-
-
50549087736
-
Growth stimulation leads to cellular senescence when the cell cycle is blocked
-
Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008; 7: 3355-3361.
-
(2008)
Cell Cycle
, vol.7
, pp. 3355-3361
-
-
Demidenko, Z.N.1
Blagosklonny, M.V.2
-
124
-
-
67649316033
-
Rapamycin decelerates cellular senescence
-
Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009; 8: 1888-1895.
-
(2009)
Cell Cycle
, vol.8
, pp. 1888-1895
-
-
Demidenko, Z.N.1
Zubova, S.G.2
Bukreeva, E.I.3
Pospelov, V.A.4
Pospelova, T.V.5
Blagosklonny, M.V.6
-
125
-
-
67649369064
-
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence
-
Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle. 2009; 8: 1896-1900.
-
(2009)
Cell Cycle
, vol.8
, pp. 1896-1900
-
-
Demidenko, Z.N.1
Shtutman, M.2
Blagosklonny, M.V.3
-
126
-
-
77953111224
-
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential
-
Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY). 2009; 1: 1008- 1016.
-
(2009)
Aging (Albany NY)
, vol.1
, pp. 1008-1016
-
-
Demidenko, Z.N.1
Blagosklonny, M.V.2
-
127
-
-
74849091341
-
Pseudo-DNA damage response in senescent cells
-
Pospelova TV, Demidenk ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle. 2009; 8: 4112-4118.
-
(2009)
Cell Cycle
, vol.8
, pp. 4112-4118
-
-
Pospelova, T.V.1
Demidenk, Z.N.2
Bukreeva, E.I.3
Pospelov, V.A.4
Gudkov, A.V.5
Blagosklonny, M.V.6
-
129
-
-
77955747085
-
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
-
Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY). 2010; 2: 344-352.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 344-352
-
-
Korotchkina, L.G.1
Leontieva, O.V.2
Bukreeva, E.I.3
Demidenko, Z.N.4
Gudkov, A.V.5
Blagosklonny, M.V.6
-
130
-
-
79952269372
-
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
-
Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY). 2010; 2: 924-935.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 924-935
-
-
Leontieva, O.V.1
Blagosklonny, M.V.2
-
131
-
-
78349286289
-
Weak p53 permits senescence during cell cycle arrest
-
Leontieva O, Gudkov A, Blagosklonny M. Weak p53 permits senescence during cell cycle arrest. Cell Cycle. 2010; 9: 4323-4327.
-
(2010)
Cell Cycle
, vol.9
, pp. 4323-4327
-
-
Leontieva, O.1
Gudkov, A.2
Blagosklonny, M.3
-
132
-
-
67649316034
-
Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration
-
Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle. 2009; 8: 1883-1887.
-
(2009)
Cell Cycle
, vol.8
, pp. 1883-1887
-
-
Blagosklonny, M.V.1
-
133
-
-
79952260219
-
mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
-
Wesierska-Gadek J. mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging. Aging (Albany NY). 2010; 2: 892-893.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 892-893
-
-
Wesierska-Gadek, J.1
-
134
-
-
79952116991
-
TP53 and MTOR crosstalk to regulate cellular senescence
-
Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY). 2010; 2: 535-537.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 535-537
-
-
Galluzzi, L.1
Kepp, O.2
Kroemer, G.3
-
135
-
-
50549090486
-
Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells
-
Blagosklonny MV. Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells. Rejuvenation Res. 2008; 11: 801-808.
-
(2008)
Rejuvenation Res
, vol.11
, pp. 801-808
-
-
Blagosklonny, M.V.1
-
136
-
-
75549090275
-
mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells
-
Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009; 2: ra75.
-
(2009)
Sci Signal
, vol.2
-
-
Chen, C.1
Liu, Y.2
Zheng, P.3
-
137
-
-
58049196780
-
mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization
-
Gan B, Sahin E, Jiang S, Sanchez-Aguilera A, Scott KL, Chin L, Williams DA, Kwiatkowski DJ, DePinho RA. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A. 2008; 105: 19384-19389.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 19384-19389
-
-
Gan, B.1
Sahin, E.2
Jiang, S.3
Sanchez-Aguilera, A.4
Scott, K.L.5
Chin, L.6
Williams, D.A.7
Kwiatkowski, D.J.8
DePinho, R.A.9
-
138
-
-
65949104286
-
mTORC1 signaling governs hematopoietic stem cell quiescence
-
Gan B, DePinho RA. mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle. 2009; 8: 1003-1006.
-
(2009)
Cell Cycle
, vol.8
, pp. 1003-1006
-
-
Gan, B.1
DePinho, R.A.2
-
139
-
-
69249206717
-
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging
-
Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009; 5: 279- 289.
-
(2009)
Cell Stem Cell
, vol.5
, pp. 279-289
-
-
Castilho, R.M.1
Squarize, C.H.2
Chodosh, L.A.3
Williams, B.O.4
Gutkind, J.S.5
-
140
-
-
66149107054
-
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR
-
Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE, Walsh K, Moskowitz MA, Liao JK. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009; 2: ra11.
-
(2009)
Sci Signal
, vol.2
-
-
Wang, C.Y.1
Kim, H.H.2
Hiroi, Y.3
Sawada, N.4
Salomone, S.5
Benjamin, L.E.6
Walsh, K.7
Moskowitz, M.A.8
Liao, J.K.9
-
141
-
-
79959776029
-
Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells
-
Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011; 3: 89ra58.
-
(2011)
Sci Transl Med
, vol.3
-
-
Cao, K.1
Graziotto, J.J.2
Blair, C.D.3
Mazzulli, J.R.4
Erdos, M.R.5
Krainc, D.6
Collins, F.S.7
-
142
-
-
77953149043
-
Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans)
-
Blagosklonny MV. Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle. 2010; 9: 683-688.
-
(2010)
Cell Cycle
, vol.9
, pp. 683-688
-
-
Blagosklonny, M.V.1
-
143
-
-
79952118049
-
Adult-onset, short-term dietary restriction reduces cell senescence in mice
-
Wang C, Maddick M, Miwa S, Jurk D, Czapiewski R, Saretzki G, Langie SA, Godschalk RW, Cameron K, von Zglinicki T. Adult-onset, short-term dietary restriction reduces cell senescence in mice. Aging (Albany NY). 2010; 2: 555-566.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 555-566
-
-
Wang, C.1
Maddick, M.2
Miwa, S.3
Jurk, D.4
Czapiewski, R.5
Saretzki, G.6
Langie, S.A.7
Godschalk, R.W.8
Cameron, K.9
von Zglinicki, T.10
-
144
-
-
79952117538
-
Perspectives on cellular senescence and short term dietary restriction in adults
-
Kirkland JL. Perspectives on cellular senescence and short term dietary restriction in adults. Aging (Albany NY). 2010; 2: 542-544.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 542-544
-
-
Kirkland, J.L.1
-
145
-
-
84891713034
-
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor
-
CoppŽ JP, Patil CK, Rodier F, Sun Y, Mu-oz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008; 6: 2853-2868.
-
(2008)
PLoS Biol
, vol.6
, pp. 2853-2868
-
-
CoppŽ, J.P.1
Patil, C.K.2
Rodier, F.3
Sun, Y.4
Mu-oz, D.P.5
Goldstein, J.6
Nelson, P.S.7
Desprez, P.Y.8
Campisi, J.9
-
146
-
-
0035834121
-
Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging
-
Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001; 98: 12072-12077.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 12072-12077
-
-
Krtolica, A.1
Parrinello, S.2
Lockett, S.3
Desprez, P.Y.4
Campisi, J.5
-
147
-
-
67649318940
-
MicroRNAs miR- 146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8
-
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J. MicroRNAs miR- 146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY). 2009; 1: 402-411.
-
(2009)
Aging (Albany NY)
, vol.1
, pp. 402-411
-
-
Bhaumik, D.1
Scott, G.K.2
Schokrpur, S.3
Patil, C.K.4
Orjalo, A.V.5
Rodier, F.6
Lithgow, G.J.7
Campisi, J.8
-
148
-
-
68249096784
-
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
-
Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009; 11: 973-979.
-
(2009)
Nat Cell Biol
, vol.11
, pp. 973-979
-
-
Rodier, F.1
Coppe, J.P.2
Patil, C.K.3
Hoeijmakers, W.A.4
Munoz, D.P.5
Raza, S.R.6
Freund, A.7
Campeau, E.8
Davalos, A.R.9
Campisi, J.10
-
149
-
-
78651104478
-
DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion
-
Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, Coppe JP, Campeau E, Beausejour CM, Kim SH, Davalos AR, Campisi J. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci. 2011; 124: 68-81.
-
(2011)
J Cell Sci
, vol.124
, pp. 68-81
-
-
Rodier, F.1
Munoz, D.P.2
Teachenor, R.3
Chu, V.4
Le, O.5
Bhaumik, D.6
Coppe, J.P.7
Campeau, E.8
Beausejour, C.M.9
Kim, S.H.10
Davalos, A.R.11
Campisi, J.12
-
150
-
-
20444437233
-
p53 is a suppressor of inflammatory response in mice
-
Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV. p53 is a suppressor of inflammatory response in mice. Faseb J. 2005; 19: 1030- 1032.
-
(2005)
Faseb J
, vol.19
, pp. 1030-1032
-
-
Komarova, E.A.1
Krivokrysenko, V.2
Wang, K.3
Neznanov, N.4
Chernov, M.V.5
Komarov, P.G.6
Brennan, M.L.7
Golovkina, T.V.8
Rokhlin, O.W.9
Kuprash, D.V.10
Nedospasov, S.A.11
Hazen, S.L.12
Feinstein, E.13
Gudkov, A.V.14
-
151
-
-
77957581129
-
Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction
-
Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging (Albany NY). 2010; 2: 361-368.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 361-368
-
-
Ye, J.1
Keller, J.N.2
-
152
-
-
80052093232
-
Reversing the aging stromal phenotype prevents carcinoma initiation
-
Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY). 2011; 3: 407- 416.
-
(2011)
Aging (Albany NY)
, vol.3
, pp. 407-416
-
-
Lewis, D.A.1
Travers, J.B.2
Machado, C.3
Somani, A.K.4
Spandau, D.F.5
-
153
-
-
79961099905
-
From growing to secreting: new roles for mTOR in aging cells
-
Pani G. From growing to secreting: new roles for mTOR in aging cells. Cell Cycle. 2011; 10: 2450-2453.
-
(2011)
Cell Cycle
, vol.10
, pp. 2450-2453
-
-
Pani, G.1
-
154
-
-
79959996812
-
Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine
-
Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle. 2011; 10: 2059- 2063.
-
(2011)
Cell Cycle
, vol.10
, pp. 2059-2063
-
-
Lisanti, M.P.1
Martinez-Outschoorn, U.E.2
Pavlides, S.3
Whitaker-Menezes, D.4
Pestell, R.G.5
Howell, A.6
Sotgia, F.7
-
155
-
-
4544343980
-
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
-
Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004; 14: 1650-1656.
-
(2004)
Curr Biol
, vol.14
, pp. 1650-1656
-
-
Shah, O.J.1
Wang, Z.2
Hunter, T.3
-
156
-
-
24144446404
-
Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability
-
Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, WaldhŠusl W, Marette A, Roden M. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes. 2005; 54: 2674-2684.
-
(2005)
Diabetes
, vol.54
, pp. 2674-2684
-
-
Tremblay, F.1
Krebs, M.2
Dombrowski, L.3
Brehm, A.4
Bernroider, E.5
Roth, E.6
Nowotny, P.7
WaldhŠusl, W.8
Marette, A.9
Roden, M.10
-
157
-
-
34249679233
-
The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man
-
Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, Roth E, FŸrnsinn C, Promintzer M, Anderwald C, Bischof M, Roden M. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007; 56: 1600-1607.
-
(2007)
Diabetes
, vol.56
, pp. 1600-1607
-
-
Krebs, M.1
Brunmair, B.2
Brehm, A.3
Artwohl, M.4
Szendroedi, J.5
Nowotny, P.6
Roth, E.7
Fÿrnsinn, C.8
Promintzer, M.9
Anderwald, C.10
Bischof, M.11
Roden, M.12
-
158
-
-
34548092167
-
Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes
-
Mordier S, Iynedjian PB. Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. Biochem Biophys Res Commun. 2007; 362: 206-211.
-
(2007)
Biochem Biophys Res Commun
, vol.362
, pp. 206-211
-
-
Mordier, S.1
Iynedjian, P.B.2
-
159
-
-
84055190702
-
Rapamycin-induced glucose intolerance: Hunger or starvation diabetes
-
Blagosklonny MV. Rapamycin-induced glucose intolerance: Hunger or starvation diabetes. Cell Cycle. 2011; 10: 4217- 4224.
-
(2011)
Cell Cycle
, vol.10
, pp. 4217-4224
-
-
Blagosklonny, M.V.1
-
160
-
-
78650744017
-
Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis
-
Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J. Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis. Proc Natl Acad Sci U S A. 2010; 107: 21713-21718.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 21713-21718
-
-
Henry, C.J.1
Marusyk, A.2
Zaberezhnyy, V.3
Adane, B.4
DeGregori, J.5
-
161
-
-
80055110647
-
Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection?
-
Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection? Aging (Albany NY). 2011; 3: 643-656.
-
(2011)
Aging (Albany NY)
, vol.3
, pp. 643-656
-
-
Henry, C.J.1
Marusyk, A.2
DeGregori, J.3
-
162
-
-
74549205329
-
Validation of anti-aging drugs by treating age-related diseases
-
Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY). 2009; 1: 281-288.
-
(2009)
Aging (Albany NY)
, vol.1
, pp. 281-288
-
-
Blagosklonny, M.V.1
-
163
-
-
78650352864
-
Increasing healthy lifespan by suppressing aging in our lifetime: Preliminary proposal
-
Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: Preliminary proposal. Cell Cycle. 2010; 9: 4788-4794.
-
(2010)
Cell Cycle
, vol.9
, pp. 4788-4794
-
-
Blagosklonny, M.V.1
-
164
-
-
0642367846
-
Genetics: influence of TOR kinase on lifespan in C. elegans
-
Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003; 426: 620.
-
(2003)
Nature
, vol.426
, pp. 620
-
-
Vellai, T.1
Takacs-Vellai, K.2
Zhang, Y.3
Kovacs, A.L.4
Orosz, L.5
Muller, F.6
-
165
-
-
30944458446
-
Extension of chronological life span in yeast by decreased TOR pathway signaling
-
Powers RW, 2nd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 2006; 20: 174-184.
-
(2006)
Genes Dev
, vol.20
, pp. 174-184
-
-
Powers II, R.W.1
Kaeberlein, M.2
Caldwell, S.D.3
Kennedy, B.K.4
Fields, S.5
-
166
-
-
27744511769
-
Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients
-
Kaeberlein M, Powers RWr, K. K. S, Westman EA, Hu D, Dang N, Kerr EO, Kirkland KT, Fields S, Kennedy BK. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005; 310: 1193-1196.
-
(2005)
Science
, vol.310
, pp. 1193-1196
-
-
Kaeberlein, M.1
Powers 3rd, R.W.2
Steffen, K.K.3
Westman, E.A.4
Hu, D.5
Dang, N.6
Kerr, E.O.7
Kirkland, K.T.8
Fields, S.9
Kennedy, B.K.10
-
167
-
-
4544311861
-
The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span
-
Jia K, Chen D, Riddle DL. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development. 2004; 131: 3897-3906.
-
(2004)
Development
, vol.131
, pp. 3897-3906
-
-
Jia, K.1
Chen, D.2
Riddle, D.L.3
-
168
-
-
3042648746
-
Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway
-
Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004; 14: 885-890.
-
(2004)
Curr Biol
, vol.14
, pp. 885-890
-
-
Kapahi, P.1
Zid, B.M.2
Harper, T.3
Koslover, D.4
Sapin, V.5
Benzer, S.6
-
169
-
-
68049109688
-
Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density
-
Pan Y, Shadel GS. Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density. Aging (Albany NY). 2009; 1: 131-145.
-
(2009)
Aging (Albany NY)
, vol.1
, pp. 131-145
-
-
Pan, Y.1
Shadel, G.S.2
-
170
-
-
67650944993
-
Rapamycin fed late in life extends lifespan in genetically heterogenous mice
-
Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandezr E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature. 2009; 460: 392-396.
-
(2009)
Nature
, vol.460
, pp. 392-396
-
-
Harrison, D.E.1
Strong, R.2
Sharp, Z.D.3
Nelson, J.F.4
Astle, C.M.5
Flurkey, K.6
Nadon, N.L.7
Wilkinson, J.E.8
Frenkel, K.9
Carter, C.S.10
Pahor, M.11
Javors, M.A.12
Fernandezr, E.13
Miller, R.A.14
-
171
-
-
59649120539
-
Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans
-
Honjoh S, Yamamoto T, Uno M, Nishida E. Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans. Nature. 2009; 457: 726-730.
-
(2009)
Nature
, vol.457
, pp. 726-730
-
-
Honjoh, S.1
Yamamoto, T.2
Uno, M.3
Nishida, E.4
-
172
-
-
65549122452
-
Insulin sensitivity as a key mediator of growth hormone actions on longevity
-
Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin sensitivity as a key mediator of growth hormone actions on longevity. J Gerontol A Biol Sci Med Sci. 2009; 64: 516-521.
-
(2009)
J Gerontol A Biol Sci Med Sci
, vol.64
, pp. 516-521
-
-
Masternak, M.M.1
Panici, J.A.2
Bonkowski, M.S.3
Hughes, L.F.4
Bartke, A.5
-
173
-
-
65349191234
-
Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways
-
Estep PWr, Warner JB, Bulyk ML. Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways. PLoS One. 2009; 4: e5242.
-
(2009)
PLoS One
, vol.4
-
-
Estep, P.W.R.1
Warner, J.B.2
Bulyk, M.L.3
-
174
-
-
70349669095
-
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span
-
Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009; 326: 140-144.
-
(2009)
Science
, vol.326
, pp. 140-144
-
-
Selman, C.1
Tullet, J.M.2
Wieser, D.3
Irvine, E.4
Lingard, S.J.5
Choudhury, A.I.6
Claret, M.7
Al-Qassab, H.8
Carmignac, D.9
Ramadani, F.10
Woods, A.11
Robinson, I.C.12
Schuster, E.13
Batterham, R.L.14
Kozma, S.C.15
Thomas, G.16
-
175
-
-
77952380764
-
Pharmacological Inhibition of Phosphoinositide 3 and TOR Kinases Improves Survival of Drosophila melanogaster
-
Moskalev AA, Shaposhnikov MV. Pharmacological Inhibition of Phosphoinositide 3 and TOR Kinases Improves Survival of Drosophila melanogaster. Rejuvenation Res. 2010; 13: 246-247.
-
(2010)
Rejuvenation Res
, vol.13
, pp. 246-247
-
-
Moskalev, A.A.1
Shaposhnikov, M.V.2
-
176
-
-
72649091698
-
Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster
-
Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010; 11: 35-46.
-
(2010)
Cell Metab
, vol.11
, pp. 35-46
-
-
Bjedov, I.1
Toivonen, J.M.2
Kerr, F.3
Slack, C.4
Jacobson, J.5
Foley, A.6
Partridge, L.7
-
177
-
-
79951794971
-
Rapamycin, But Not Resveratrol or Simvastatin Extends Life Span of Genetically Heterogeneous Mice
-
Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE et al. Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice. J Gerontol A Biol Sci Med Sci. 2011; 66: 191-201.
-
(2011)
J Gerontol A Biol Sci Med Sci
, vol.66
, pp. 191-201
-
-
Miller, R.A.1
Harrison, D.E.2
Astle, C.M.3
Baur, J.A.4
Boyd, A.R.5
de Cabo, R.6
Fernandez, E.7
Flurkey, K.8
Javors, M.A.9
Nelson, J.F.10
Orihuela, C.J.11
Pletcher, S.12
Sharp, Z.D.13
Sinclair, D.14
Starnes, J.W.15
Wilkinson, J.E.16
-
178
-
-
77952083662
-
Rapamycin extends maximal lifespan in cancer-prone mice
-
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010; 176: 2092-2097.
-
(2010)
Am J Pathol
, vol.176
, pp. 2092-2097
-
-
Anisimov, V.N.1
Zabezhinski, M.A.2
Popovich, I.G.3
Piskunova, T.S.4
Semenchenko, A.V.5
Tyndyk, M.L.6
Yurova, M.N.7
Antoch, M.P.8
Blagosklonny, M.V.9
-
179
-
-
83755165458
-
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
-
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011; 10: 4230-4236.
-
(2011)
Cell Cycle
, vol.10
, pp. 4230-4236
-
-
Anisimov, V.N.1
Zabezhinski, M.A.2
Popovich, I.G.3
Piskunova, T.S.4
Semenchenko, A.V.5
Tyndyk, M.L.6
Yurova, M.N.7
Blagosklonny, M.V.8
-
180
-
-
77955747346
-
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging
-
Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 2010; 11: 453-465.
-
(2010)
Cell Metab
, vol.11
, pp. 453-465
-
-
Kapahi, P.1
Chen, D.2
Rogers, A.N.3
Katewa, S.D.4
Li, P.W.5
Thomas, E.L.6
Kockel, L.7
-
181
-
-
77953645579
-
Rapamycin and quasi-programmed aging: Four years later
-
Blagosklonny MV. Rapamycin and quasi-programmed aging: Four years later. Cell Cycle. 2010; 9: 1859-1862.
-
(2010)
Cell Cycle
, vol.9
, pp. 1859-1862
-
-
Blagosklonny, M.V.1
-
182
-
-
79953231709
-
A longer and healthier life with TOR down-regulation: genetics and drugs
-
Bjedov I, Partridge L. A longer and healthier life with TOR down-regulation: genetics and drugs. Biochem Soc Trans. 2011; 39: 460-465.
-
(2011)
Biochem Soc Trans
, vol.39
, pp. 460-465
-
-
Bjedov, I.1
Partridge, L.2
-
183
-
-
79954632599
-
Role of TOR signaling in aging and related biological processes in Drosophila melanogaster
-
Katewa SD, Kapahi P. Role of TOR signaling in aging and related biological processes in Drosophila melanogaster. Exp Gerontol. 2011; 46: 382-390.
-
(2011)
Exp Gerontol
, vol.46
, pp. 382-390
-
-
Katewa, S.D.1
Kapahi, P.2
-
184
-
-
20444459116
-
Antitumor activity of rapamycin in a transgenic mouse model of ErbB2- dependent human breast cancer
-
Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, Oshima RG, Abraham RT. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2- dependent human breast cancer. Cancer Res. 2005; 65: 5325-5336.
-
(2005)
Cancer Res
, vol.65
, pp. 5325-5336
-
-
Liu, M.1
Howes, A.2
Lesperance, J.3
Stallcup, W.B.4
Hauser, C.A.5
Kadoya, K.6
Oshima, R.G.7
Abraham, R.T.8
-
185
-
-
34047253075
-
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
-
Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007; 67: 2408-2413.
-
(2007)
Cancer Res
, vol.67
, pp. 2408-2413
-
-
Mabuchi, S.1
Altomare, D.A.2
Connolly, D.C.3
Klein-Szanto, A.4
Litwin, S.5
Hoelzle, M.K.6
Hensley, H.H.7
Hamilton, T.C.8
Testa, J.R.9
-
186
-
-
34548089170
-
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2- positive breast cancer
-
Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2- positive breast cancer. Mol Cancer Ther. 2007; 6: 2188- 2197.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2188-2197
-
-
Mosley, J.D.1
Poirier, J.T.2
Seachrist, D.D.3
Landis, M.D.4
Keri, R.A.5
-
187
-
-
34247520866
-
Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors
-
Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res. 2007; 13: 2281-2289.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2281-2289
-
-
Granville, C.A.1
Warfel, N.2
Tsurutani, J.3
Hollander, M.C.4
Robertson, M.5
Fox, S.D.6
Veenstra, T.D.7
Issaq, H.J.8
Linnoila, R.I.9
Dennis, P.A.10
-
188
-
-
33750884079
-
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer
-
Chollet P, Abrial C, Tacca O, Mouret-Reynier MA, Leheurteur M, Durando X, Cure H. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer. 2006; 7: 336-338.
-
(2006)
Clin Breast Cancer
, vol.7
, pp. 336-338
-
-
Chollet, P.1
Abrial, C.2
Tacca, O.3
Mouret-Reynier, M.A.4
Leheurteur, M.5
Durando, X.6
Cure, H.7
-
189
-
-
78649816080
-
Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes
-
Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer. 2010; 17: 941-951.
-
(2010)
Endocr Relat Cancer
, vol.17
, pp. 941-951
-
-
Fierz, Y.1
Novosyadlyy, R.2
Vijayakumar, A.3
Yakar, S.4
LeRoith, D.5
-
190
-
-
67749110462
-
Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice
-
Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J Pathol. 2009; 219: 35-40.
-
(2009)
J Pathol
, vol.219
, pp. 35-40
-
-
Robinson, J.1
Lai, C.2
Martin, A.3
Nye, E.4
Tomlinson, I.5
Silver, A.6
-
191
-
-
83755206860
-
Rapamycin: Killing two birds with one stone
-
Khanna A, Kapahi P. Rapamycin: Killing two birds with one stone. Aging (Albany NY). 2011; 3: 1043-4.
-
(2011)
Aging (Albany NY)
, vol.3
, pp. 1043-1044
-
-
Khanna, A.1
Kapahi, P.2
-
192
-
-
79960085339
-
Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer
-
Lashinger LM, Malone LM, Brown GW, Daniels EA, Goldberg JA, Otto G, Fischer SM, Hursting SD. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila). 2011; 4: 1041-1051.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, pp. 1041-1051
-
-
Lashinger, L.M.1
Malone, L.M.2
Brown, G.W.3
Daniels, E.A.4
Goldberg, J.A.5
Otto, G.6
Fischer, S.M.7
Hursting, S.D.8
-
193
-
-
27644436740
-
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
-
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005; 80: 883- 889.
-
(2005)
Transplantation
, vol.80
, pp. 883-889
-
-
Kauffman, H.M.1
Cherikh, W.S.2
Cheng, Y.3
Hanto, D.W.4
Kahan, B.D.5
-
194
-
-
33645458234
-
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation
-
Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation. J Am Soc Nephrol. 2006; 17: 581-589.
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 581-589
-
-
Campistol, J.M.1
Eris, J.2
Oberbauer, R.3
Friend, P.4
Hutchison, B.5
Morales, J.M.6
Claesson, K.7
Stallone, G.8
Russ, G.9
Rostaing, L.10
Kreis, H.11
Burke, J.T.12
Brault, Y.13
Scarola, J.A.14
Neylan, J.F.15
-
195
-
-
20144367584
-
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
-
Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005; 352: 1317-1323.
-
(2005)
N Engl J Med
, vol.352
, pp. 1317-1323
-
-
Stallone, G.1
Schena, A.2
Infante, B.3
Di Paolo, S.4
Loverre, A.5
Maggio, G.6
Ranieri, E.7
Gesualdo, L.8
Schena, F.P.9
Grandaliano, G.10
-
196
-
-
50849110457
-
Prevention of cancer by inhibiting aging
-
Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008; 7: 1520-1524.
-
(2008)
Cancer Biol Ther
, vol.7
, pp. 1520-1524
-
-
Blagosklonny, M.V.1
-
197
-
-
36348950449
-
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells
-
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67: 10804-10812.
-
(2007)
Cancer Res
, vol.67
, pp. 10804-10812
-
-
Dowling, R.J.1
Zakikhani, M.2
Fantus, I.G.3
Pollak, M.4
Sonenberg, N.5
-
198
-
-
60749108023
-
The antidiabetic drug metformin suppresses HER2 (erbB- 2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells
-
Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB- 2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009; 8: 88-96.
-
(2009)
Cell Cycle
, vol.8
, pp. 88-96
-
-
Vazquez-Martin, A.1
Oliveras-Ferraros, C.2
Menendez, J.A.3
-
199
-
-
77955287742
-
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
-
Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11: 390-401.
-
(2010)
Cell Metab
, vol.11
, pp. 390-401
-
-
Kalender, A.1
Selvaraj, A.2
Kim, S.Y.3
Gulati, P.4
Brule, S.5
Viollet, B.6
Kemp, B.E.7
Bardeesy, N.8
Dennis, P.9
Schlager, J.J.10
Marette, A.11
Kozma, S.C.12
Thomas, G.13
-
200
-
-
79959764729
-
independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
-
Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti- Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71: 4366-4372.
-
(2011)
Cancer Res
, vol.71
, pp. 4366-4372
-
-
Ben Sahra, I.1
Regazzetti, C.2
Robert, G.3
Laurent, K.4
Le Marchand-Brustel, Y.5
Auberger, P.6
Tanti, J.F.7
Giorgetti-Peraldi, S.8
Metformin, B.F.9
-
201
-
-
0017843134
-
Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats
-
Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, Bobrov JF, Pliss GB. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch. 1978; 48: 1-8.
-
(1978)
Arch Geschwulstforsch
, vol.48
, pp. 1-8
-
-
Dilman, V.M.1
Berstein, L.M.2
Zabezhinski, M.A.3
Alexandrov, V.A.4
Bobrov, J.F.5
Pliss, G.B.6
-
202
-
-
0018895934
-
Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice
-
Dilman VM, Anisimov VN. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology. 1980; 26: 241-246.
-
(1980)
Gerontology
, vol.26
, pp. 241-246
-
-
Dilman, V.M.1
Anisimov, V.N.2
-
203
-
-
24644475793
-
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
-
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005; 40: 685-693.
-
(2005)
Exp Gerontol
, vol.40
, pp. 685-693
-
-
Anisimov, V.N.1
Berstein, L.M.2
Egormin, P.A.3
Piskunova, T.S.4
Popovich, I.G.5
Zabezhinski, M.A.6
Kovalenko, I.G.7
Poroshina, T.E.8
Semenchenko, A.V.9
Provinciali, M.10
Re, F.11
Franceschi, C.12
-
204
-
-
25444462729
-
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice
-
Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med. 2005; 139: 721-723.
-
(2005)
Bull Exp Biol Med
, vol.139
, pp. 721-723
-
-
Anisimov, V.N.1
Egormin, P.A.2
Bershtein, L.M.3
Zabezhinskii, M.A.4
Piskunova, T.S.5
Popovich, I.G.6
Semenchenko, A.V.7
-
205
-
-
50849113473
-
Metformin slows down aging and extends life span of female SHR mice
-
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008; 7: 2769-2773.
-
(2008)
Cell Cycle
, vol.7
, pp. 2769-2773
-
-
Anisimov, V.N.1
Berstein, L.M.2
Egormin, P.A.3
Piskunova, T.S.4
Popovich, I.G.5
Zabezhinski, M.A.6
Tyndyk, M.L.7
Yurova, M.V.8
Kovalenko, I.G.9
Poroshina, T.E.10
Semenchenko, A.V.11
-
206
-
-
78650316639
-
Metformin for aging and cancer prevention
-
Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2: 760-774.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 760-774
-
-
Anisimov, V.N.1
-
207
-
-
79952265105
-
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice
-
Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, Poroshina TE, Berstein LM. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY). 2010; 2: 945-958.
-
(2010)
Aging (Albany NY)
, vol.2
, pp. 945-958
-
-
Anisimov, V.N.1
Piskunova, T.S.2
Popovich, I.G.3
Zabezhinski, M.A.4
Tyndyk, M.L.5
Egormin, P.A.6
Yurova, M.V.7
Rosenfeld, S.V.8
Semenchenko, A.V.9
Kovalenko, I.G.10
Poroshina, T.E.11
Berstein, L.M.12
-
208
-
-
74549131244
-
Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo
-
Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010; 9: 188-197.
-
(2010)
Cell Cycle
, vol.9
, pp. 188-197
-
-
Anisimov, V.N.1
Egormin, P.A.2
Piskunova, T.S.3
Popovich, I.G.4
Tyndyk, M.L.5
Yurova, M.N.6
Zabezhinski, M.A.7
Anikin, I.V.8
Karkach, A.S.9
Romanyukha, A.A.10
-
209
-
-
77956415337
-
Metformin prevents tobacco carcinogen-- induced lung tumorigenesis
-
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-- induced lung tumorigenesis. Cancer Prev Res (Phila). 2010; 3: 1066-1076.
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 1066-1076
-
-
Memmott, R.M.1
Mercado, J.R.2
Maier, C.R.3
Kawabata, S.4
Fox, S.D.5
Dennis, P.A.6
-
211
-
-
20444461067
-
Metformin and reduced risk of cancer in diabetic patients
-
Evans JM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
-
(2005)
BMJ
, vol.330
, pp. 1304-1305
-
-
Evans, J.M.1
-
212
-
-
69549097703
-
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes
-
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625
-
(2009)
Diabetes Care
, vol.32
, pp. 1620-1625
-
-
Libby, G.1
Donnelly, L.A.2
Donnan, P.T.3
Alessi, D.R.4
Morris, A.D.5
Evans, J.M.6
-
213
-
-
66949126138
-
Metformin, insulin, breast cancer and more
-
Berstein LM. Metformin, insulin, breast cancer and more. Future Oncol. 2009; 5: 309-312.
-
(2009)
Future Oncol
, vol.5
, pp. 309-312
-
-
Berstein, L.M.1
-
214
-
-
77956312069
-
Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond
-
Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol. 2010; 6: 1313-1323.
-
(2010)
Future Oncol
, vol.6
, pp. 1313-1323
-
-
Berstein, L.M.1
-
215
-
-
84857752594
-
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer
-
He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2011.
-
(2011)
Ann Oncol
-
-
He, X.1
Esteva, F.J.2
Ensor, J.3
Hortobagyi, G.N.4
Lee, M.H.5
Yeung, S.C.6
-
216
-
-
77953971245
-
Cancer: Long-term use of metformin could protect against breast cancer
-
Koch L. Cancer: Long-term use of metformin could protect against breast cancer. Nat Rev Endocrinol. 2010; 6: 356.
-
(2010)
Nat Rev Endocrinol
, vol.6
, pp. 356
-
-
Koch, L.1
-
217
-
-
77956401999
-
Metformin and other biguanides in oncology: advancing the research agenda
-
Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila). 2010; 3: 1060-1065.
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 1060-1065
-
-
Pollak, M.1
-
218
-
-
77953527360
-
Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena
-
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010; 9: 1057-1064.
-
(2010)
Cell Cycle
, vol.9
, pp. 1057-1064
-
-
Martin-Castillo, B.1
Vazquez-Martin, A.2
Oliveras-Ferraros, C.3
Menendez, J.A.4
-
219
-
-
84858693012
-
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis
-
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34: 2323-2328.
-
(2011)
Diabetes Care
, vol.34
, pp. 2323-2328
-
-
Zhang, Z.J.1
Zheng, Z.J.2
Kan, H.3
Song, Y.4
Cui, W.5
Zhao, G.6
Kip, K.E.7
-
220
-
-
55249097866
-
Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus
-
Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am J Med Sci. 2008; 336: 241-247.
-
(2008)
Am J Med Sci
, vol.336
, pp. 241-247
-
-
Gosmanova, E.O.1
Canada, R.B.2
Mangold, T.A.3
Rawls, W.N.4
Wall, B.M.5
-
221
-
-
79959378341
-
Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice
-
Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T, Kochi T, Tsurumi H, Tanaka T, Moriwaki H. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun. 2011; 410: 108-113.
-
(2011)
Biochem Biophys Res Commun
, vol.410
, pp. 108-113
-
-
Kubota, M.1
Shimizu, M.2
Sakai, H.3
Yasuda, Y.4
Ohno, T.5
Kochi, T.6
Tsurumi, H.7
Tanaka, T.8
Moriwaki, H.9
-
222
-
-
80051786113
-
Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver
-
Mansour MA, Al-Ismaeel H, Al-Rikabi AC, Al-Shabanah OA. Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver. Life Sci. 2011; 89: 188-194.
-
(2011)
Life Sci
, vol.89
, pp. 188-194
-
-
Mansour, M.A.1
Al-Ismaeel, H.2
Al-Rikabi, A.C.3
Al-Shabanah, O.A.4
-
223
-
-
80051642134
-
Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells
-
Luo Y, Ohmori H, Shimomoto T, Fujii K, Sasahira T, Chihara Y, Kuniyasu H. Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells. Pathobiology. 2011; 78: 285-290.
-
(2011)
Pathobiology
, vol.78
, pp. 285-290
-
-
Luo, Y.1
Ohmori, H.2
Shimomoto, T.3
Fujii, K.4
Sasahira, T.5
Chihara, Y.6
Kuniyasu, H.7
-
224
-
-
0036681694
-
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis
-
Miyajima A, Kosaka T, Asano T, Seta K, Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002; 62: 4176-4179.
-
(2002)
Cancer Res
, vol.62
, pp. 4176-4179
-
-
Miyajima, A.1
Kosaka, T.2
Asano, T.3
Seta, K.4
Kawai, T.5
Hayakawa, M.6
-
225
-
-
80051660023
-
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study
-
Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol. 2011; 29: 3001-3007.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3001-3007
-
-
Chang, C.H.1
Lin, J.W.2
Wu, L.C.3
Lai, M.S.4
-
226
-
-
79952773620
-
Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension
-
Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011; 107: 1028-1033.
-
(2011)
Am J Cardiol
, vol.107
, pp. 1028-1033
-
-
Huang, C.C.1
Chan, W.L.2
Chen, Y.C.3
Chen, T.J.4
Lin, S.J.5
Chen, J.W.6
Leu, H.B.7
-
227
-
-
77952659304
-
Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients
-
Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, Bertoni E, Salvadori M. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol. 2010; 73: 439-445.
-
(2010)
Clin Nephrol
, vol.73
, pp. 439-445
-
-
Moscarelli, L.1
Zanazzi, M.2
Mancini, G.3
Rossi, E.4
Caroti, L.5
Rosso, G.6
Bertoni, E.7
Salvadori, M.8
-
228
-
-
0026083978
-
Angiotensin and cell growth: a link to cardiovascular hypertrophy?
-
Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991; 9: 3-15.
-
(1991)
J Hypertens
, vol.9
, pp. 3-15
-
-
Schelling, P.1
Fischer, H.2
Ganten, D.3
-
229
-
-
0028907314
-
Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells
-
Giasson E, Meloche S. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem. 1995; 270: 5225-5231.
-
(1995)
J Biol Chem
, vol.270
, pp. 5225-5231
-
-
Giasson, E.1
Meloche, S.2
-
231
-
-
0030045372
-
Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes
-
Takano H, Komuro I, Zou Y, Kudoh S, Yamazaki T, Yazaki Y. Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes. FEBS Lett. 1996; 379: 255-259.
-
(1996)
FEBS Lett
, vol.379
, pp. 255-259
-
-
Takano, H.1
Komuro, I.2
Zou, Y.3
Kudoh, S.4
Yamazaki, T.5
Yazaki, Y.6
-
232
-
-
0033601182
-
Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt
-
Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, Inagami T. Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem. 1999; 274: 36843-36851.
-
(1999)
J Biol Chem
, vol.274
, pp. 36843-36851
-
-
Eguchi, S.1
Iwasaki, H.2
Ueno, H.3
Frank, G.D.4
Motley, E.D.5
Eguchi, K.6
Marumo, F.7
Hirata, Y.8
Inagami, T.9
-
233
-
-
0036784081
-
Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells
-
Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol. 2002; 62: 772-777.
-
(2002)
Mol Pharmacol
, vol.62
, pp. 772-777
-
-
Haider, U.G.1
Sorescu, D.2
Griendling, K.K.3
Vollmar, A.M.4
Dirsch, V.M.5
-
234
-
-
1642396747
-
Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells
-
Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol. 2003; 478: 39-46.
-
(2003)
Eur J Pharmacol
, vol.478
, pp. 39-46
-
-
Yamakawa, T.1
Tanaka, S.2
Kamei, J.3
Kadonosono, K.4
Okuda, K.5
-
235
-
-
84855301496
-
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation
-
Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab. 2011; 302: E201-208.
-
(2011)
Am J Physiol Endocrinol Metab
, vol.302
-
-
Kim, J.A.1
Jang, H.J.2
Martinez-Lemus, L.A.3
Sowers, J.R.4
-
236
-
-
79959652692
-
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin
-
Whaley-Connell A, Habibi J, Panfili Z, Hayden MR, Bagree S, Nistala R, Hyder S, Krueger B, Demarco V, Pulakat L, Ferrario CM, Parrish A, Sowers JR. Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol. 2011; 34: 115- 125.
-
(2011)
Am J Nephrol
, vol.34
, pp. 115-125
-
-
Whaley-Connell, A.1
Habibi, J.2
Panfili, Z.3
Hayden, M.R.4
Bagree, S.5
Nistala, R.6
Hyder, S.7
Krueger, B.8
Demarco, V.9
Pulakat, L.10
Ferrario, C.M.11
Parrish, A.12
Sowers, J.R.13
-
237
-
-
84858428443
-
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
-
Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, Andre N. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2010; 2: 797-809.
-
(2010)
Oncotarget
, vol.2
, pp. 797-809
-
-
Pasquier, E.1
Ciccolini, J.2
Carre, M.3
Giacometti, S.4
Fanciullino, R.5
Pouchy, C.6
Montero, M.P.7
Serdjebi, C.8
Kavallaris, M.9
Andre, N.10
-
238
-
-
79953658412
-
Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival
-
Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010; 1: 628-638.
-
(2010)
Oncotarget
, vol.1
, pp. 628-638
-
-
Powe, D.G.1
Voss, M.J.2
Zanker, K.S.3
Habashy, H.O.4
Green, A.R.5
Ellis, I.O.6
Entschladen, F.7
-
239
-
-
80052190882
-
Targeted therapies: Using beta-blockers to inhibit breast cancer progression
-
Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011; 8: 511-512.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 511-512
-
-
Powe, D.G.1
Entschladen, F.2
-
240
-
-
79960141295
-
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
-
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011; 29: 2645-2652.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2645-2652
-
-
Melhem-Bertrandt, A.1
Chavez-Macgregor, M.2
Lei, X.3
Brown, E.N.4
Lee, R.T.5
Meric-Bernstam, F.6
Sood, A.K.7
Conzen, S.D.8
Hortobagyi, G.N.9
Gonzalez-Angulo, A.M.10
-
241
-
-
79960138447
-
Beta blockers and breast cancer mortality: a population-based study
-
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011; 29: 2635-2644.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2635-2644
-
-
Barron, T.I.1
Connolly, R.M.2
Sharp, L.3
Bennett, K.4
Visvanathan, K.5
-
242
-
-
79953647658
-
Beta-adrenergic signaling, a novel target for cancer therapy?
-
Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget. 2010; 1: 466-469.
-
(2010)
Oncotarget
, vol.1
, pp. 466-469
-
-
Schuller, H.M.1
-
243
-
-
0032190906
-
Activation of p70(S6) kinase by beta-adrenoceptor agonists on adult cardiomyocytes
-
Simm A, Schluter K, Diez C, Piper HM, Hoppe J. Activation of p70(S6) kinase by beta-adrenoceptor agonists on adult cardiomyocytes. J Mol Cell Cardiol. 1998; 30: 2059-2067.
-
(1998)
J Mol Cell Cardiol
, vol.30
, pp. 2059-2067
-
-
Simm, A.1
Schluter, K.2
Diez, C.3
Piper, H.M.4
Hoppe, J.5
-
244
-
-
0034672474
-
beta-agonists regulate Na K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways
-
Pesce L, Guerrero C, Comellas A, Ridge KM, Sznajder JI. beta-agonists regulate Na,K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways. FEBS Lett. 2000; 486: 310-314.
-
(2000)
FEBS Lett
, vol.486
, pp. 310-314
-
-
Pesce, L.1
Guerrero, C.2
Comellas, A.3
Ridge, K.M.4
Sznajder, J.I.5
-
246
-
-
60749136576
-
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study
-
Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009; 101: 267-276.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 267-276
-
-
Grau, M.V.1
Sandler, R.S.2
McKeown-Eyssen, G.3
Bresalier, R.S.4
Haile, R.W.5
Barry, E.L.6
Ahnen, D.J.7
Gui, J.8
Summers, R.W.9
Baron, J.A.10
-
247
-
-
82055176773
-
A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark
-
Chang ET, Froslev T, Sorensen HT, Pedersen L. A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark. Br J Cancer. 2011; 105: 1776-1782.
-
(2011)
Br J Cancer
, vol.105
, pp. 1776-1782
-
-
Chang, E.T.1
Froslev, T.2
Sorensen, H.T.3
Pedersen, L.4
-
248
-
-
83955161674
-
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
-
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378: 2081-2087.
-
(2011)
Lancet
, vol.378
, pp. 2081-2087
-
-
Burn, J.1
Gerdes, A.M.2
Macrae, F.3
Mecklin, J.P.4
Moeslein, G.5
Olschwang, S.6
Eccles, D.7
Evans, D.G.8
Maher, E.R.9
Bertario, L.10
Bisgaard, M.L.11
Dunlop, M.G.12
Ho, J.W.13
Hodgson, S.V.14
Lindblom, A.15
Lubinski, J.16
-
249
-
-
78650825618
-
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
-
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377: 31-41.
-
(2011)
Lancet
, vol.377
, pp. 31-41
-
-
Rothwell, P.M.1
Fowkes, F.G.2
Belch, J.F.3
Ogawa, H.4
Warlow, C.P.5
Meade, T.W.6
-
250
-
-
34248157118
-
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
-
Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369: 1603-1613.
-
(2007)
Lancet
, vol.369
, pp. 1603-1613
-
-
Flossmann, E.1
Rothwell, P.M.2
-
251
-
-
81555195411
-
Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study
-
Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, Petersen GM. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila). 2011; 4: 1835-1841.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, pp. 1835-1841
-
-
Tan, X.L.1
Reid Lombardo, K.M.2
Bamlet, W.R.3
Oberg, A.L.4
Robinson, D.P.5
Anderson, K.E.6
Petersen, G.M.7
-
252
-
-
60749128400
-
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials
-
Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009; 101: 256- 266.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 256-266
-
-
Cole, B.F.1
Logan, R.F.2
Halabi, S.3
Benamouzig, R.4
Sandler, R.S.5
Grainge, M.J.6
Chaussade, S.7
Baron, J.A.8
-
253
-
-
0034624043
-
Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen
-
Law BK, Waltner-Law ME, Entingh AJ, Chytil A, Aakre ME, Norgaard P, Moses HL. Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen. J Biol Chem. 2000; 275: 38261-38267.
-
(2000)
J Biol Chem
, vol.275
, pp. 38261-38267
-
-
Law, B.K.1
Waltner-Law, M.E.2
Entingh, A.J.3
Chytil, A.4
Aakre, M.E.5
Norgaard, P.6
Moses, H.L.7
-
254
-
-
40349085518
-
Obesity, metabolic syndrome, and prostate cancer
-
Hsing AW, Sakoda LC, Chua S, Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007; 86: s843-857.
-
(2007)
Am J Clin Nutr
, vol.86
-
-
Hsing, A.W.1
Sakoda, L.C.2
Chua Jr., S.3
-
255
-
-
37049013701
-
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study
-
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Bmj. 2007; 335: 1134.
-
(2007)
Bmj
, vol.335
, pp. 1134
-
-
Reeves, G.K.1
Pirie, K.2
Beral, V.3
Green, J.4
Spencer, E.5
Bull, D.6
-
256
-
-
54849431380
-
Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration
-
Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 2008; 8: 399-410.
-
(2008)
Cell Metab
, vol.8
, pp. 399-410
-
-
Polak, P.1
Cybulski, N.2
Feige, J.N.3
Auwerx, J.4
Ruegg, M.A.5
Hall, M.N.6
-
257
-
-
38949108241
-
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
-
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578.
-
(2008)
Lancet
, vol.371
, pp. 569-578
-
-
Renehan, A.G.1
Tyson, M.2
Egger, M.3
Heller, R.F.4
Zwahlen, M.5
-
260
-
-
54849433477
-
Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link
-
Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP, Perkins SN. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab. 2008; 22: 659-669.
-
(2008)
Best Pract Res Clin Endocrinol Metab
, vol.22
, pp. 659-669
-
-
Hursting, S.D.1
Lashinger, L.M.2
Wheatley, K.W.3
Rogers, C.J.4
Colbert, L.H.5
Nunez, N.P.6
Perkins, S.N.7
-
261
-
-
35348832340
-
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance
-
Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A. 2007; 104: 14056-14061.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 14056-14061
-
-
Tremblay, F.1
Brule, S.2
Hee Um, S.3
Li, Y.4
Masuda, K.5
Roden, M.6
Sun, X.J.7
Krebs, M.8
Polakiewicz, R.D.9
Thomas, G.10
Marette, A.11
-
262
-
-
0035851205
-
Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway A negative feedback mechanism leading to insulin resistance in skeletal muscle cells
-
Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001; 276: 38052-38060.
-
(2001)
J Biol Chem
, vol.276
, pp. 38052-38060
-
-
Tremblay, F.1
Marette, A.2
-
263
-
-
33750155593
-
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase
-
Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006; 25: 6361-6372.
-
(2006)
Oncogene
, vol.25
, pp. 6361-6372
-
-
Avruch, J.1
Hara, K.2
Lin, Y.3
Liu, M.4
Long, X.5
Ortiz-Vega, S.6
Yonezawa, K.7
-
264
-
-
33645738458
-
Complexity of the TOR signaling network
-
Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol. 2006; 16: 206-212.
-
(2006)
Trends Cell Biol
, vol.16
, pp. 206-212
-
-
Inoki, K.1
Guan, K.L.2
-
265
-
-
56549109059
-
Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues
-
Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, DiGiovanni J. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila). 2008; 1: 65-76.
-
(2008)
Cancer Prev Res (Phila)
, vol.1
, pp. 65-76
-
-
Moore, T.1
Beltran, L.2
Carbajal, S.3
Strom, S.4
Traag, J.5
Hursting, S.D.6
DiGiovanni, J.7
-
266
-
-
78650848337
-
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
-
Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature. 2010; 468: 1100-1104.
-
(2010)
Nature
, vol.468
, pp. 1100-1104
-
-
Sengupta, S.1
Peterson, T.R.2
Laplante, M.3
Oh, S.4
Sabatini, D.M.5
-
267
-
-
4544220704
-
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
-
Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004; 431: 200-205.
-
(2004)
Nature
, vol.431
, pp. 200-205
-
-
Um, S.H.1
Frigerio, F.2
Watanabe, M.3
Picard, F.4
Joaquin, M.5
Sticker, M.6
Fumagalli, S.7
Allegrini, P.R.8
Kozma, S.C.9
Auwerx, J.10
Thomas, G.11
-
268
-
-
14244256097
-
Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance
-
Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005; 146: 1473-1481.
-
(2005)
Endocrinology
, vol.146
, pp. 1473-1481
-
-
Khamzina, L.1
Veilleux, A.2
Bergeron, S.3
Marette, A.4
-
269
-
-
34249679614
-
mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer
-
Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med. 2007; 13: 252-259.
-
(2007)
Trends Mol Med
, vol.13
, pp. 252-259
-
-
Dann, S.G.1
Selvaraj, A.2
Thomas, G.3
-
270
-
-
77951971550
-
Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats
-
Ma L, Ma S, He H, Yang D, Chen X, Luo Z, Liu D, Zhu Z. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res. 2010; 33: 446-453.
-
(2010)
Hypertens Res
, vol.33
, pp. 446-453
-
-
Ma, L.1
Ma, S.2
He, H.3
Yang, D.4
Chen, X.5
Luo, Z.6
Liu, D.7
Zhu, Z.8
-
272
-
-
78650510609
-
mTOR: from growth signal integration to cancer, diabetes and ageing
-
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12: 21-35.
-
(2011)
Nat Rev Mol Cell Biol
, vol.12
, pp. 21-35
-
-
Zoncu, R.1
Efeyan, A.2
Sabatini, D.M.3
-
273
-
-
77958449473
-
p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate
-
Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, Fornace AJ, Jr., Pospelova TV, Pospelov VA. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle. 2010; 9: 3945-3955.
-
(2010)
Cell Cycle
, vol.9
, pp. 3945-3955
-
-
Romanov, V.S.1
Abramova, M.V.2
Svetlikova, S.B.3
Bykova, T.V.4
Zubova, S.G.5
Aksenov, N.D.6
Fornace Jr., A.J.7
Pospelova, T.V.8
Pospelov, V.A.9
-
274
-
-
33745307617
-
PI(3)K and mTOR signalling controls tumour cell growth
-
Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441: 424-430.
-
(2006)
Nature
, vol.441
, pp. 424-430
-
-
Shaw, R.J.1
Ras, C.L.C.2
-
275
-
-
78349261103
-
Targeting TOR dependence in cancer
-
Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget. 2010; 1: 69-76.
-
(2010)
Oncotarget
, vol.1
, pp. 69-76
-
-
Janes, M.R.1
Fruman, D.A.2
-
276
-
-
79957983577
-
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs
-
Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2010; 1: 530-543.
-
(2010)
Oncotarget
, vol.1
, pp. 530-543
-
-
Markman, B.1
Dienstmann, R.2
Tabernero, J.3
-
277
-
-
33644513730
-
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
-
Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6: 184- 192.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 184-192
-
-
Cully, M.1
You, H.2
Levine, A.J.3
Mak, T.W.4
-
278
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9-22.
-
(2007)
Cancer Cell
, vol.12
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
280
-
-
79952087950
-
PI3Kalpha inhibitors that inhibit metastasis
-
Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S. PI3Kalpha inhibitors that inhibit metastasis. Oncotarget. 2010; 1: 339-348.
-
(2010)
Oncotarget
, vol.1
, pp. 339-348
-
-
Schmidt-Kittler, O.1
Zhu, J.2
Yang, J.3
Liu, G.4
Hendricks, W.5
Lengauer, C.6
Gabelli, S.B.7
Kinzler, K.W.8
Vogelstein, B.9
Huso, D.L.10
Zhou, S.11
-
281
-
-
79958016002
-
A beta version of life: p110beta takes center stage
-
Dbouk HA, Backer JM. A beta version of life: p110beta takes center stage. Oncotarget. 2010; 1: 729-733.
-
(2010)
Oncotarget
, vol.1
, pp. 729-733
-
-
Dbouk, H.A.1
Backer, J.M.2
-
282
-
-
77957819681
-
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
-
Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010; 1: 89-103.
-
(2010)
Oncotarget
, vol.1
, pp. 89-103
-
-
Martelli, A.M.1
Evangelisti, C.2
Chiarini, F.3
McCubrey, J.A.4
-
283
-
-
79957447410
-
P3Kalpha: a driver of tumor metastasis?
-
Zawel L. P3Kalpha: a driver of tumor metastasis? Oncotarget. 2010; 1: 315-316.
-
(2010)
Oncotarget
, vol.1
, pp. 315-316
-
-
Zawel, L.1
-
284
-
-
70449907014
-
The role of mTORC1 pathway in intestinal tumorigenesis
-
Fujishita T, Aoki M, Taketo MM. The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle. 2009; 8: 3684-3687
-
(2009)
Cell Cycle
, vol.8
, pp. 3684-3687
-
-
Fujishita, T.1
Aoki, M.2
Taketo, M.M.3
|